TOP TEN perturbations for 38543_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38543_at
Selected probe(set): 208212_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38543_at (208212_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

lung adenocarcinoma study 5 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):5.042506
Number of Samples:3 / 20
Experimental lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

lung adenocarcinoma study 6 (EGFR mut) / lung adenocarcinoma study 6 (EML4-ALK)

Relative Expression (log2-ratio):-4.9959774
Number of Samples:24 / 8
Experimental lung adenocarcinoma study 6 (EGFR mut)
Primary tumor sample from patients with stage II adenocarcinoma carrying an EGFR mutation.
Control lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.

lung adenocarcinoma study 5 (EGFR mut) / lung adenocarcinoma study 5 (EML4-ALK)

Relative Expression (log2-ratio):-4.991205
Number of Samples:103 / 3
Experimental lung adenocarcinoma study 5 (EGFR mut)
Primary tumor sample from patients with stage I adenocarcinoma carrying an EGFR mutation.
Control lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.

lung adenocarcinoma study 6 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):4.9298353
Number of Samples:8 / 20
Experimental lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

lung adenocarcinoma study 6 (EML4-ALK) / lung adenocarcinoma study 6 (EGFR/K-RAS/ALK -)

Relative Expression (log2-ratio):4.9138927
Number of Samples:8 / 20
Experimental lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.
Control lung adenocarcinoma study 6 (EGFR/K-RAS/ALK -)
Primary tumor sample from patients with triple-negative stage II adenocarcinoma of the lung. The patients were not carrying any mutation in the EGFR, K- RAS or ALK gene.

lung adenocarcinoma study 5 (EML4-ALK) / lung adenocarcinoma study 5 (EGFR/K-RAS/ALK -)

Relative Expression (log2-ratio):4.9070683
Number of Samples:3 / 48
Experimental lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control lung adenocarcinoma study 5 (EGFR/K-RAS/ALK -)
Primary tumor sample from patients with triple-negative stage I adenocarcinoma of the lung. The patients were not carrying any mutation in the EGFR, K- RAS or ALK gene.

lung adenocarcinoma study 5 (K-RAS mut) / lung adenocarcinoma study 5 (EML4-ALK)

Relative Expression (log2-ratio):-4.8807516
Number of Samples:14 / 3
Experimental lung adenocarcinoma study 5 (K-RAS mut)
Primary tumor sample from patients with stage I adenocarcinoma carrying a K-RAS mutation.
Control lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.

basal cell carcinoma study 2 / normal skin tissue

Relative Expression (log2-ratio):4.8320255
Number of Samples:2 / 64
Experimental basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).
Control normal skin tissue
Normal skin samples from healthy donors.

lung adenocarcinoma study 6 (K-RAS mut) / lung adenocarcinoma study 6 (EML4-ALK)

Relative Expression (log2-ratio):-4.4821672
Number of Samples:6 / 8
Experimental lung adenocarcinoma study 6 (K-RAS mut)
Primary tumor sample from patients with stage II adenocarcinoma carrying a K-RAS mutation.
Control lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.

E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):-3.6711426
Number of Samples:5 / 7
Experimental E. coli study 2
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.